New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations related to MYQORZO™ (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place March 28–30, 2026 in New Orleans, LA. Recently approved for the treatment of adults with symptomatic obstructive hypertrophic c ...

Core Insights - The launch of MYQORZO has been ongoing for about a month, with early signs being encouraging [1] - Key metrics are being monitored, with a focus on awareness among targeted cardiologists [1] Group 1: Launch Metrics - MYQORZO was launched in late January, and the company is only a month into the launch [1] - Over 90% awareness of MYQORZO has been reported among high-volume prescribers of Camzyos, indicating strong recognition in the target market [1]

Cytokinetics FY Conference Summary Company Overview - **Company**: Cytokinetics (NasdaqGS:CYTK) - **Focus**: Development and commercialization of cardiac myosin inhibitors, specifically MYQORZO (aficamten) Key Industry Insights - **Launch of MYQORZO**: - Launched in late January 2026, with early metrics showing over 90% awareness among high-volume prescribers of CAMZYOS, the existing cardiac myosin inhibitor [4][5] - Over 700 cardiologists have completed the REMS program and are already dispensing MYQORZO [5] - Initial prescriptions are coming from both established prescribers and new prescribers, indicating strong interest [5] Core Points and Arguments - **Market Awareness and Adoption**: - High awareness of MYQORZO among targeted cardiologists suggests a strong potential for adoption [4] - Early signs of interest include requests for information on switching patients from CAMZYOS to MYQORZO [5][7] - **Differentiation from Competitors**: - MYQORZO offers a different physician and patient experience, particularly in terms of speed of onset and dosing flexibility [16][20] - The promotion strategy focuses on safety, efficacy, and a unique experience for both physicians and patients [20] - **Financial Strategy**: - The company has strengthened its balance sheet through strategic partnerships and successful financing efforts, allowing for investment in both U.S. and European launches [26] - Plans to launch in Germany in Q2 2026, with ongoing investments in understanding market dynamics in Europe [25][26] Pipeline Developments - **ACACIA-HCM Study**: - Represents an opportunity for MYQORZO to demonstrate clinical safety and efficacy in non-obstructive hypertrophic cardiomyopathy (NHCM) [29] - The study is designed to address dosing challenges specific to NHCM, with a focus on maximum tolerated doses [32][34] - Positive phase 2 data has been observed, with improvements in biomarkers and patient-reported outcomes [35] - **Future Pipeline**: - Omecamtiv mecarbil is in a confirmatory phase 3 study for advanced heart failure, with a large patient population at high risk of mortality [52] - Ulacamten is being studied in heart failure with preserved ejection fraction (HFpEF), indicating a robust pipeline focused on specialty cardiology [53][54] Strategic Vision - **Independent Operations in Europe**: - Cytokinetics aims to operate independently in Europe, believing it can achieve profitability through strategic pricing and market understanding [48][49] - The company is focused on building a specialty cardiology franchise, leveraging its expertise and pipeline to create a valuable enterprise [49][50] Additional Considerations - **Potential Halo Effect**: - Success in the ACACIA-HCM study could positively influence MYQORZO sales in obstructive hypertrophic cardiomyopathy (OHCM) by reinforcing clinical efficacy [42][46] - **Long-term Goals**: - The company is committed to growing its top line responsibly while fulfilling fiduciary obligations to shareholders [58] This summary encapsulates the key points discussed during the Cytokinetics FY Conference, highlighting the company's strategic direction, market positioning, and pipeline developments.

Summary of Cytokinetics Conference Call Company Overview - **Company**: Cytokinetics - **Recent Achievement**: Approval of the first drug, Myqorzo, for obstructive hypertrophic cardiomyopathy (OHCM) [2][26] Key Points Clinical Trials and Market Potential - **Upcoming Trials**: Results from the ACACIA-HCM study for non-obstructive hypertrophic cardiomyopathy (NHCM) are expected in Q2 [2][4] - **Market Size**: NHCM represents approximately 50% of the diagnosed and symptomatic patient population for hypertrophic cardiomyopathy in the U.S., with an estimated 100,000 patients eligible for Myqorzo treatment [2][3] - **Competition**: Myqorzo enters a market with existing competition from BMS's Camzyos, which generated over $1 billion in sales last year [3][4] - **Study Insights**: The ODYSSEY-HCM trial for Camzyos in NHCM was unsuccessful, but it provides a benchmark for Cytokinetics' ACACIA trial [4][11] Drug Development and Mechanism - **Drug Mechanism**: Both OHCM and NHCM share similar disease pathologies, including thickening of the heart and diastolic dysfunction, which may allow for effective treatment with cardiac myosin inhibitors [6][8] - **Dosing Strategy**: The ACACIA trial employs a maximum tolerated dose strategy, which was successful in the Phase II trial with no significant adverse effects [10][12] Launch and Commercialization - **Launch Strategy**: Myqorzo was launched with a focus on ease of use and a favorable safety profile compared to Camzyos, including a REMS program that simplifies monitoring for physicians [26][27] - **Early Feedback**: Initial feedback indicates strong engagement from cardiologists, with over 700 participating in the REMS program and many writing prescriptions shortly after launch [28][29] - **Market Awareness**: Market research shows over 90% awareness among healthcare professionals, suggesting a strong demand for Myqorzo [29] Future Directions - **Next-Gen Compound**: Cytokinetics is developing ulacamten, a cardiac myosin inhibitor targeting heart failure with preserved ejection fraction (HFpEF), which shares characteristics with NHCM [35][36] - **Strategic Vision**: The company aims to build a specialty cardiology franchise focused on myosin modulation, leveraging its pioneering position in the field [39] Additional Insights - **Patient Outcomes**: The ACACIA trial's design includes measures to avoid pitfalls seen in previous trials, such as high placebo effects and inconsistent patient exposure [12][13] - **Long-Term Strategy**: Cytokinetics plans to expand its market presence from OHCM to NHCM and eventually to advanced heart failure populations, aligning with its long-term strategic goals [39]

Company Overview - Cytokinetics is a late-stage biopharmaceutical company focusing on muscle biology and developing novel therapeutics for cardiac and neuromuscular conditions [7] - The company has a market capitalization of $7.62 billion and reported a revenue of $87.21 million with a net income loss of $785 million for the trailing twelve months [4] - The company operates a business model centered on drug discovery, clinical development, and potential commercialization, primarily generating revenue from research collaborations and milestone payments [10] Recent Transaction - On February 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer, exercised 15,000 stock options and sold the shares for approximately $928,950 [1][2] - The transaction involved a weighted average sale price of around $61.93 per share, slightly above the market close of $60.24 on the same day [5] - Following the sale, Callos' direct ownership decreased from 65,440 to 50,440 shares, representing a direct equity stake of 0.04% of shares outstanding [5] Market Context - The timing of the transaction is notable as it occurred shortly after the FDA approval of myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, which had seen a stock surge of over 92% in the preceding six months [9] - Myqorzo became available by U.S. prescription in January 2026, marking a significant milestone for Cytokinetics as a commercial-stage business [10] - The company is at a critical inflection point, appealing to investors with a higher risk tolerance interested in specialty cardiovascular plays with potential for significant returns [11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Core Insights - Cytokinetics (CYTK) reported a net loss of $1.50 per share for Q4 2025, wider than the Zacks Consensus Estimate of a loss of $1.48, and an increase from a loss of $1.26 per share in the same quarter last year [1] - Revenues for the quarter totaled $17.7 million, significantly exceeding the Zacks Consensus Estimate of $4 million, and reflecting a 5% increase year-over-year [2] - The company ended 2025 with approximately $1.22 billion in cash, providing substantial runway for commercialization and clinical development [5] Financial Performance - R&D expenses rose to $104.4 million, an 11.5% increase year-over-year, driven by advancing clinical programs and higher personnel costs [4] - General and administrative expenses surged 47.2% year-over-year to $91.7 million, primarily due to investments in commercial launch readiness and corporate infrastructure expansion [4] - For the full year 2025, revenues increased to $88 million from $18.5 million in 2024, driven by milestone payments and collaboration activities [6] Product Development and Approvals - The FDA approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in December 2025, marking a significant milestone for the company [8] - Myqorzo has also received authorization in China and the EU, with a planned launch in Germany in Q2 2026 [8] - The company is pursuing label expansion for Myqorzo with a supplemental new drug application (sNDA) for MAPLE-HCM, expecting potential approval in Q4 2026 [9] Clinical Trials and Pipeline - Ongoing studies include ACACIA-HCM, a phase III study of aficamten in non-obstructive HCM, with top-line results expected in Q2 2026 [10] - Other pipeline candidates include omecamtiv mecarbil for heart failure, with a confirmatory phase III trial ongoing [12] - Enrollment is also ongoing for AMBER-HFpEF, a phase II study on ulacamten in patients with preserved ejection fraction [13] Market Position and Future Outlook - The approval of Myqorzo positions Cytokinetics as a key player in the growing specialty cardiology market, which has historically had limited pharmacologic options [14] - With a strong cash position and multiple near-term catalysts, the company is poised for a transformation into a revenue-generating biotech in 2026 [15] - Successful commercialization of Myqorzo is critical, as it will face competition from Bristol Myers Squibb's Camzyos, which has performed well since its approval [16]

Group 1 - E.ON plans to increase investments to 48 billion euros ($57 billion) over the next five years to expand and modernize energy grids [1][2] - The new investment plan for 2026 to 2030 is an increase from the previous 43 billion euro program for 2024 to 2028, indicating a strategic focus on enhancing regulated networks [2] - CEO Leonhard Birnbaum emphasized the need for a secure, affordable, and resilient energy system as it becomes larger, more decentralized, and complex [1]

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.63%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.59 per share when it actually produced a loss of $1.54, delivering a surprise of +3.14%.Over the last four quarters, the comp ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $17.8 million, up from $16.9 million in Q4 2024, while total revenues for the full year 2025 reached $88 million, compared to $18.5 million in 2024, primarily due to technology transfer and milestone recognition [27][28] - R&D expenses for Q4 2025 were $104.4 million, an increase from $93.6 million in Q4 2024, and for the full year, R&D expenses rose to $416 million from $339.4 million in 2024 [29] - G&A expenses for Q4 2025 were $91.7 million, compared to $62.3 million in Q4 2024, with full-year G&A expenses at $284.3 million, up from $215.3 million in 2024 [29] - The net loss for Q4 2025 was $183 million or $1.50 per share, compared to a net loss of $150 million or $1.26 per share in Q4 2024, with a full-year net loss of $785 million or $6.54 per share, compared to $589.5 million or $5.26 per share in 2024 [30] Business Line Data and Key Metrics Changes - The approval of MYQORZO represents a significant milestone, marking the company's transition to a global commercial-stage biopharmaceutical company [5][6] - The U.S. commercial launch of MYQORZO began immediately after FDA approval, with a focus on building customer support systems and marketing campaigns [10][12] - Initial customer feedback has been positive, with over 700 healthcare providers (HCPs) certified in the REMS program within three weeks of launch, indicating strong engagement and demand [13][14] Market Data and Key Metrics Changes - The company anticipates launching MYQORZO in Germany in Q2 2026, following its recent approval in the EU [7][18] - The company has engaged with key payers to ensure access for MYQORZO, aiming for Medicare access comparable to Camzyos by Q1 2026 and commercial access by Q4 2026 [17] Company Strategy and Development Direction - The company is focused on executing the launch of MYQORZO while advancing its muscle biology pipeline, with a disciplined approach to capital allocation [8][32] - The strategic priorities include launching MYQORZO in the U.S. and Europe, advancing clinical trials for aficamten, and investing in the muscle biology platform [32][33] - The company aims to achieve greater than 50% of CMI new patient preference share by the end of 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial prospects for MYQORZO, citing strong initial engagement from the cardiology community and a high level of interest in the new treatment option [6][13] - The company is closely monitoring the operating environment and is optimistic about the potential for MYQORZO to address significant unmet medical needs in obstructive HCM [7][36] Other Important Information - The company is committed to addressing disparities in access to care for patients with HCM through a three-year initiative with the American Heart Association [36] - The company plans to report top-line results from ACACIA-HCM in Q2 2026 and expects to receive potential FDA approval for the supplemental NDA for MAPLE-HCM by Q4 2026 [37] Q&A Session Summary Question: Is it true that the ACACIA-HCM study will be successful if at least one of the endpoints reaches statistical significance? - Management confirmed that the trial will be deemed positive if it hits on either or both of the pre-specified clinical trial endpoints [41][42][43] Question: Could you share any color on how long it's taking sites to get through the REMS certification for MYQORZO? - Management noted that REMS certification is a quick process, generally taking 10-20 minutes, and many HCPs were prepared to certify quickly due to prior experience with similar products [47][48][49] Question: What are the expectations for the placebo arm response in ACACIA-HCM? - Management indicated that they are blinded to the data but noted that previous studies showed minimal placebo response, and the trial is designed to focus on the difference between active and placebo responses [55][58] Question: How is the early market uptake for MYQORZO in the U.S.? - Management reported that demand is in line with expectations, with many patients ready to start treatment following approval [66][68] Question: What is the significance of a potential win in ACACIA-HCM for the broader HFpEF opportunity? - Management highlighted that success in ACACIA-HCM could inform expectations for HFpEF and the potential benefits of cardiac myosin inhibitors in that population [95][96]